Home » Newsletters » BioWorld Science

BioWorld Science

March 31, 2014

View Archived Issues

Protein silencing via targeted ubiquitination

Southwest Research Institute receives contract extension for cyanide antidote

Merck & Co. licenses NanoBio's adjuvant technology for use in RSV and influenza vaccines

Novartis presents data for the nAChR partial agonist AQW-051

Merck & Co. presents preclinical and phase I data for MK-1064

Scientists at Roche design novel LPA1 receptor antagonists

VITA contract supports Pulmokine's development of PDGF receptor inhibitor for PAH

Phase III fertility study of Pergoveris in poor ovarian responders begins

Halozyme reports topline data from phase I/II study of HTI-501 for cellulite

Phase II study investigates MLN-0128 for advanced CRPC

Genentech initiates phase I study of DLYE-5953A for refractory solid tumors

Phase II study investigates CPX-351 for relapsed/refractory higher risk MDS and AML

Subcutaneous MabThera approved in Europe for two forms of NHL

EMA validates MolMed's TK cell/gene therapy submission for conditional approval

Pivotal phase III Kiobrina study does not meet primary endpoint

Novel BTK inhibitors patented by Principia Biopharma

GSK withdraws MAA for combined use of Mekinist and Tafinlar

BioNumerik Pharmaceuticals divulges new camptothecin analogues

Neotope Biosciences discloses new anti-MCAM MAbs

AM-Pharma reports phase I data for recombinant human alkaline phosphatase

Baxter to create two separate global healthcare companies

RG-7813 enters first clinical trial for cancer

FDA committee votes against approval of Novartis's RLX-030 for AHF

European Commission approves Latuda for schizophrenia

FDA approves Alprolix for hemophilia B

TAS-205, a novel H-PGDS inhibitor with promising activity in animal models of allergic rhinitis

Terbinafine transungual solution active in a phase IIb study

Popular Stories

Today's news in brief
BioWorld
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...